vs
Side-by-side financial comparison of AtriCure, Inc. (ATRC) and Core Laboratories Inc. (CLB). Click either name above to swap in a different company.
AtriCure, Inc. is the larger business by last-quarter revenue ($140.5M vs $121.8M, roughly 1.2× Core Laboratories Inc.). On growth, AtriCure, Inc. posted the faster year-over-year revenue change (13.1% vs -1.4%). AtriCure, Inc. produced more free cash flow last quarter ($18.4M vs $517.0K). Over the past eight quarters, AtriCure, Inc.'s revenue compounded faster (13.6% CAGR vs -3.4%).
AtriCure, Inc. is a global medical device company specializing in the research, development, and manufacturing of innovative surgical tools and therapeutic solutions for treating atrial fibrillation and associated cardiac conditions. Its core customers include hospitals, cardiac surgery centers, and healthcare providers across North America, Europe, and the Asia Pacific region, with products designed to support safer, more effective minimally invasive cardiac procedures.
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.
ATRC vs CLB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $140.5M | $121.8M |
| Net Profit | — | $5.1M |
| Gross Margin | 75.0% | — |
| Operating Margin | 1.8% | 1.5% |
| Net Margin | — | 4.2% |
| Revenue YoY | 13.1% | -1.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.04 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $121.8M | ||
| Q4 25 | $140.5M | $138.3M | ||
| Q3 25 | $134.3M | $134.5M | ||
| Q2 25 | $136.1M | $130.2M | ||
| Q1 25 | $123.6M | $123.6M | ||
| Q4 24 | $124.3M | $129.2M | ||
| Q3 24 | $115.9M | $134.4M | ||
| Q2 24 | $116.3M | $130.6M |
| Q1 26 | — | $5.1M | ||
| Q4 25 | — | $4.9M | ||
| Q3 25 | $-267.0K | $14.2M | ||
| Q2 25 | $-6.2M | $10.6M | ||
| Q1 25 | $-6.7M | $-154.0K | ||
| Q4 24 | — | $7.4M | ||
| Q3 24 | $-7.9M | $11.7M | ||
| Q2 24 | $-8.0M | $9.0M |
| Q1 26 | — | — | ||
| Q4 25 | 75.0% | 20.8% | ||
| Q3 25 | 75.5% | 22.0% | ||
| Q2 25 | 74.5% | 20.3% | ||
| Q1 25 | 74.9% | 19.5% | ||
| Q4 24 | 74.5% | 17.8% | ||
| Q3 24 | 74.9% | 20.5% | ||
| Q2 24 | 74.7% | 21.2% |
| Q1 26 | — | 1.5% | ||
| Q4 25 | 1.8% | 11.5% | ||
| Q3 25 | 0.2% | 15.6% | ||
| Q2 25 | -4.5% | 11.7% | ||
| Q1 25 | -4.8% | 3.6% | ||
| Q4 24 | -11.7% | 11.0% | ||
| Q3 24 | -6.4% | 14.7% | ||
| Q2 24 | -6.2% | 12.3% |
| Q1 26 | — | 4.2% | ||
| Q4 25 | — | 3.6% | ||
| Q3 25 | -0.2% | 10.6% | ||
| Q2 25 | -4.5% | 8.2% | ||
| Q1 25 | -5.5% | -0.1% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | -6.8% | 8.7% | ||
| Q2 24 | -6.9% | 6.9% |
| Q1 26 | — | $0.11 | ||
| Q4 25 | $0.04 | $0.11 | ||
| Q3 25 | $-0.01 | $0.30 | ||
| Q2 25 | $-0.13 | $0.22 | ||
| Q1 25 | $-0.14 | $0.00 | ||
| Q4 24 | $-0.33 | $0.15 | ||
| Q3 24 | $-0.17 | $0.25 | ||
| Q2 24 | $-0.17 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.4M | $22.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $491.9M | $275.1M |
| Total Assets | $654.2M | $587.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $22.8M | ||
| Q4 25 | $167.4M | $22.7M | ||
| Q3 25 | $147.9M | $25.6M | ||
| Q2 25 | $117.8M | $31.2M | ||
| Q1 25 | $99.9M | $22.1M | ||
| Q4 24 | $122.7M | $19.2M | ||
| Q3 24 | $130.3M | $21.5M | ||
| Q2 24 | $114.0M | $17.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $110.3M | ||
| Q3 25 | $61.9M | $114.1M | ||
| Q2 25 | $61.9M | $124.6M | ||
| Q1 25 | $61.9M | $124.4M | ||
| Q4 24 | — | $126.1M | ||
| Q3 24 | $61.9M | $139.9M | ||
| Q2 24 | $61.9M | $147.6M |
| Q1 26 | — | $275.1M | ||
| Q4 25 | $491.9M | $266.0M | ||
| Q3 25 | $476.5M | $271.3M | ||
| Q2 25 | $464.5M | $261.3M | ||
| Q1 25 | $454.6M | $253.4M | ||
| Q4 24 | $461.0M | $246.6M | ||
| Q3 24 | $465.0M | $250.7M | ||
| Q2 24 | $462.1M | $240.3M |
| Q1 26 | — | $587.7M | ||
| Q4 25 | $654.2M | $584.0M | ||
| Q3 25 | $635.4M | $591.4M | ||
| Q2 25 | $608.8M | $602.1M | ||
| Q1 25 | $591.6M | $591.5M | ||
| Q4 24 | $609.3M | $585.1M | ||
| Q3 24 | $615.1M | $600.5M | ||
| Q2 24 | $597.3M | $597.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.41× | ||
| Q3 25 | 0.13× | 0.42× | ||
| Q2 25 | 0.13× | 0.48× | ||
| Q1 25 | 0.14× | 0.49× | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | 0.13× | 0.56× | ||
| Q2 24 | 0.13× | 0.61× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.0M | $4.0M |
| Free Cash FlowOCF − Capex | $18.4M | $517.0K |
| FCF MarginFCF / Revenue | 13.1% | 0.4% |
| Capex IntensityCapex / Revenue | 1.1% | — |
| Cash ConversionOCF / Net Profit | — | 0.77× |
| TTM Free Cash FlowTrailing 4 quarters | $48.3M | $22.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $4.0M | ||
| Q4 25 | $20.0M | $7.9M | ||
| Q3 25 | $26.7M | $8.5M | ||
| Q2 25 | $21.6M | $13.9M | ||
| Q1 25 | $-11.0M | $6.7M | ||
| Q4 24 | $5.8M | $20.6M | ||
| Q3 24 | $20.0M | $13.1M | ||
| Q2 24 | $7.4M | $17.1M |
| Q1 26 | — | $517.0K | ||
| Q4 25 | $18.4M | $5.0M | ||
| Q3 25 | $24.1M | $6.5M | ||
| Q2 25 | $19.0M | $10.4M | ||
| Q1 25 | $-13.2M | $3.9M | ||
| Q4 24 | $3.1M | $17.4M | ||
| Q3 24 | $16.4M | $10.4M | ||
| Q2 24 | $5.0M | $14.3M |
| Q1 26 | — | 0.4% | ||
| Q4 25 | 13.1% | 3.6% | ||
| Q3 25 | 18.0% | 4.8% | ||
| Q2 25 | 13.9% | 8.0% | ||
| Q1 25 | -10.7% | 3.1% | ||
| Q4 24 | 2.5% | 13.4% | ||
| Q3 24 | 14.1% | 7.7% | ||
| Q2 24 | 4.3% | 10.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 2.1% | ||
| Q3 25 | 1.9% | 1.5% | ||
| Q2 25 | 2.0% | 2.7% | ||
| Q1 25 | 1.8% | 2.3% | ||
| Q4 24 | 2.2% | 2.5% | ||
| Q3 24 | 3.1% | 2.0% | ||
| Q2 24 | 2.1% | 2.2% |
| Q1 26 | — | 0.77× | ||
| Q4 25 | — | 1.61× | ||
| Q3 25 | — | 0.60× | ||
| Q2 25 | — | 1.31× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.78× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.90× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATRC
| Appendage Management | $45.5M | 32% |
| Openheart | $38.5M | 27% |
| Other | $26.2M | 19% |
| Pain Management | $22.6M | 16% |
| Minimally Invasive | $7.7M | 6% |
CLB
Segment breakdown not available.
